PT  - JOURNAL ARTICLE
AU  - HIROYUKI KODAMA
AU  - TETSUJI TERAZAWA
AU  - YASUNOBU ISHIZUKA
AU  - HIROKI YUKAMI
AU  - MASAHIKO AOKI
AU  - TAKAHIRO MIYAMOTO
AU  - TOSHIFUMI YAMAGUCHI
AU  - FUTUKARO SHIMAMOTO
AU  - TAKAYUKI KII
AU  - MASAHIRO GOTO
AU  - HIROKI HAMAMOTO
AU  - WATARU OSUMI
AU  - MASASHI YAMAMOTO
AU  - KEITARO TANAKA
AU  - JYUNJI OKUDA
AU  - KAZUHISA UCHIYAMA
AU  - KAZUHIDE HIGUCHI
TI  - Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer
AID  - 10.21873/invivo.12340
DP  - 2021 Mar 01
TA  - In Vivo
PG  - 977--985
VI  - 35
IP  - 2
4099  - http://iv.iiarjournals.org/content/35/2/977.short
4100  - http://iv.iiarjournals.org/content/35/2/977.full
SO  - In Vivo2021 Mar 01; 35
AB  - Background/Aim: Neoadjuvant chemotherapy without radiation (NAC) shows favorable outcomes for locally advanced rectal cancer (LARC), however, the optimal regimen has not been determined yet. This study aimed to compare the efficacy and safety of oxaliplatin, irinotecan, folinic acid, and 5-fluorouracil (mFOLFOXIRI) with capecitabine/S-1 and oxaliplatin (XELOX/SOX) in rectal cancer patients. Patients and Methods: We retrospectively examined patients with LARC who received mFOLFOXIRI or XELOX/SOX as NAC. Results: Between January 2015 and July 2019, 49 patients received mFOLFOXIRI and 37 patients received XELOX/SOX. The pathological response rates (over two-thirds affected tumor area) were 36.7% and 40.5% in the mFOLFOXIRI and XELOX/SOX groups, respectively. Grade 3/4 neutropenia was experienced by 45.0% of the patients in the mFOLFOXIRI group and 8.0% in the XEOX/SOX group. Conclusion: Although pathological responses were comparable between two groups, mFOLFOXIRI tended to be more toxic compared to XELOX/SOX as NAC for LARC.